From palliation to targeted therapy in myelofibrosis

New England Journal of Medicine

Volumn 363, Issue 12, 2010, Pages 1180-1182

  Vannucchi, Alessandro M ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INCB 018424; INCB 028050; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; UNCLASSIFIED DRUG; CYTOKINE; PYRAZOLE DERIVATIVE; RUXOLITINIB;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; ENZYME INHIBITION; GENE MUTATION; HUMAN; MYELOFIBROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; GENETICS; INFLAMMATION; PRIMARY MYELOFIBROSIS;

CYTOKINES; HUMANS; INFLAMMATION; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PYRAZOLES;

EID: 77956664074     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1005856     Document Type: Editorial

References (10)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009;59:171-91.
2. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
3. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. Blood 2009;114:Suppl:311. abstract.
4. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology (Am Soc Hematol Educ Program) 2005:195-200.
5. Ihle JN. Cytokine receptor signalling. Nature 1995;377:591-4.
6. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83. (Pubitemid 47327415)
7. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009;10:356-60.
8. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-9.
9. Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis. Br J Haematol 2009;146:223-5.
10. Mascarenhas J, Wang X, Rodriguez A, et al. A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post-PV/ET MF). Blood 2009;114:Suppl:308. abstract.